ReviewTranslational gastroenterology and hepatology2019
Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond.
Review in Translational gastroenterology and hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A nomogram based on systemic inflammatory markers: development and validation for predicting postoperative overall survival in gastric cancer.Translational cancer research · 2026Article
- Incomplete TNM Documentation in Gastric Cancer: Frequency, Phenotype, and Treatment Allocation.Diagnostics (Basel, Switzerland) · 2026Article
- Preoperative electrolyte-based metabolic biomarkers for prognostic assessment in gastric cancer: a multicenter study.Frontiers in endocrinology · 2026Article
- Efficacy and safety of adjuvant low-dose apatinib combined with SOX regimen versus SOX regimen in patients with resectable locally advanced gastric cancer: a cohort study.Frontiers in pharmacology · 2026Article
- Preoperative prognostic assessment using intratumoral and peritumoral adipose tissue radiomics derived from contrast-enhanced CT in cT3-4 gastric cancer.Frontiers in oncology · 2025Article
- Intratumoral and peritumoral CT-based radiomics for predicting the microsatellite instability in gastric cancer.Abdominal radiology (New York) · 2024Article
- A radiomics signature derived from CT imaging to predict MSI status and immunotherapy outcomes in gastric cancer: a multi-cohort study.BMC cancer · 2024Article
- Differentially expressed microRNA in prognosis of gastric cancer with Lauren classification.Cancer biomarkers : section A of Disease markers · 2024Article
- Applying machine learning techniques to predict the risk of distant metastasis from gastric cancer: a real world retrospective study.Frontiers in oncology · 2024Article
- Dual-layer spectral-detector CT for predicting microsatellite instability status and prognosis in locally advanced gastric cancer.Insights into imaging · 2023Article
- Current management of gastric adenocarcinoma: a narrative review.Journal of gastrointestinal oncology · 2023Review
- Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.Journal of cancer research and clinical oncology · 2023Observational
- Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives.Journal of clinical medicine · 2023Review
- FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract.Journal of cancer research and clinical oncology · 2023Article
- Copy number alterations and epithelial‑mesenchymal transition genes in diffuse and intestinal gastric cancers in Mexican patients.Molecular medicine reports · 2022Article
- CT-based radiomic nomogram for preoperative prediction of DNA mismatch repair deficiency in gastric cancer.Frontiers in oncology · 2022Article
- The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancers.Frontiers in genetics · 2022Review
- Identification by Bioinformatics Analysis of Potential Key Genes Related to the Progression and Prognosis of Gastric Cancer.Frontiers in oncology · 2022Article
- Exosomal miR-487a derived from m2 macrophage promotes the progression of gastric cancer.Cell cycle (Georgetown, Tex.) · 2021Article
- Whole-exome sequencing identifies prognostic mutational signatures in gastric cancer.Annals of translational medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For accurately predicting prognosis and for effectively describing cancer states at a certain point during treatment to other care providers and patients, various staging systems have been utilized in gastric cancer. Among these, the UICC/AJCC tumor-node-metastasis (TNM) staging system is most widely used. However, even within the same substage, gastric cancers can vary substantially in regards to prognosis after treatment. For more accurate and individualized prognostication, staging systems have been found to benefit from including molecular markers and genomic subtypes, in addition to clinicopathological parameters, such as age, sex, tumor size, tumor location, Lauren classification, number of lymph nodes resected, extent of surgical resection, lymphovascular invasion, and adjuvant chemotherapy. In this review article, we review and summarize relevant biomarkers for gastric cancer that can be incorporated into the current anatomy-based TNM staging system, as well as results from validation studies thereof.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.